Big Pharma markets left on a ‘patent cliff’-h...

The US Supreme Court’s decision to strike down President Donald Trump’s use of emergency tariff powers is raising questions about existing trade deals, federal revenues, and the impact to American business. Plus, how JPMorgan chief executive Jamie Dimon is preparing to spend a re ...  Show more

Daniel Chait is the CEO of Greenhouse, a hiring platform. He told us his tips for hiring managers, a couple of unethical uses of AI in hiring and whether or not this job market is worse than the one during the global financial crisis.Mentioned in this podcast:The great graduate j ...  Show more

Four months ago, the FT’s Rob Armstrong and Elaine Moore placed their bets on two portfolios of three stocks each picked from the “Magnificent Seven” tech stocks that have been dominating markets this year. Today on the show, we check in on their portfolios, and try to think a ...

Mankind Pharma has announced it will buy biotech company BSV for a whopping Rs 13,630 crore. The deal brings together a master of mass market products and an intrinsic innovator in the high entry barrier spaces of the healthcare market. It’s an expensive buy and Mankind has gone ...  Show more

Patrick Bet-David sits down with whistleblower and author Dr. Peter C. Gøtzsche, who reveals why he calls Big Pharma “organized crime,” exposing the industry’s bribery, corruption, and dangerous practices hidden behind prescription drugs and corporate power.------🍋 ZEST IT FORWA ...  Show more

Today on Morning Brief, anchors Brad Smith and Seana Smith tackle the biggest market stories and speak to top Wall Street experts ahead of the opening bell. Our hosts analyze some of the top trending tickers: Spotify (SPOT), PepsiCo (PEP), Merck (MRK) Takeaways: China retaliates ...  Show more